MX2020002568A - Composiciones y procesos para el suministro, la expresión y la modulación dirigidos de ácidos ribonucleicos de codificación en tejido. - Google Patents
Composiciones y procesos para el suministro, la expresión y la modulación dirigidos de ácidos ribonucleicos de codificación en tejido.Info
- Publication number
- MX2020002568A MX2020002568A MX2020002568A MX2020002568A MX2020002568A MX 2020002568 A MX2020002568 A MX 2020002568A MX 2020002568 A MX2020002568 A MX 2020002568A MX 2020002568 A MX2020002568 A MX 2020002568A MX 2020002568 A MX2020002568 A MX 2020002568A
- Authority
- MX
- Mexico
- Prior art keywords
- sequence
- composition
- binding site
- expression
- modulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 229920002477 rna polymer Polymers 0.000 title 1
- 108091070501 miRNA Proteins 0.000 abstract 4
- 239000002679 microRNA Substances 0.000 abstract 4
- 108091023045 Untranslated Region Proteins 0.000 abstract 3
- 108091026890 Coding region Proteins 0.000 abstract 2
- 108020004999 messenger RNA Proteins 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 238000013459 approach Methods 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 238000002659 cell therapy Methods 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 230000000174 oncolytic effect Effects 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1714430.4A GB201714430D0 (en) | 2017-09-07 | 2017-09-07 | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| US201862632056P | 2018-02-19 | 2018-02-19 | |
| PCT/US2018/049772 WO2019051100A1 (en) | 2017-09-07 | 2018-09-06 | COMPOSITIONS AND METHODS FOR TARGETED CODING ADMINISTRATION, EXPRESSION AND MODULATION OF RIBONUCLEIC ACIDS IN TISSUE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002568A true MX2020002568A (es) | 2020-09-18 |
Family
ID=60117350
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002568A MX2020002568A (es) | 2017-09-07 | 2018-09-06 | Composiciones y procesos para el suministro, la expresión y la modulación dirigidos de ácidos ribonucleicos de codificación en tejido. |
| MX2020008606A MX2020008606A (es) | 2017-09-07 | 2019-02-19 | Composiciones y metodos para la expresion y modulacion de proteccion de organos de acidos ribonucleicos codificadores. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008606A MX2020008606A (es) | 2017-09-07 | 2019-02-19 | Composiciones y metodos para la expresion y modulacion de proteccion de organos de acidos ribonucleicos codificadores. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11359212B2 (enExample) |
| EP (2) | EP3678673B1 (enExample) |
| JP (4) | JP2020533411A (enExample) |
| KR (1) | KR102741572B1 (enExample) |
| CN (1) | CN111212650A (enExample) |
| AU (1) | AU2018328289B2 (enExample) |
| CA (1) | CA3074293A1 (enExample) |
| ES (1) | ES2942890T3 (enExample) |
| GB (1) | GB201714430D0 (enExample) |
| MX (2) | MX2020002568A (enExample) |
| PL (1) | PL3678673T3 (enExample) |
| PT (1) | PT3678673T (enExample) |
| RU (1) | RU2020112990A (enExample) |
| WO (1) | WO2019051100A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019032628A1 (en) | 2017-08-07 | 2019-02-14 | The Regents Of The University Of California | GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS |
| GB201714430D0 (en) | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| US20200376142A1 (en) * | 2018-02-19 | 2020-12-03 | Combined Therapeutics, Inc. | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids |
| JP7539723B2 (ja) | 2020-02-21 | 2024-08-26 | コンバインド セラピューティクス インコーポレイテッド | コード化リボ核酸の器官保護発現及び調節のための組成物並びに方法 |
| JP2023536844A (ja) | 2020-07-31 | 2023-08-30 | コンバインド セラピューティクス インコーポレイテッド | ワクチン接種を改善するための組成物および方法 |
| CA3171589A1 (en) | 2021-05-03 | 2022-11-03 | Moritz THRAN | Improved nucleic acid sequence for cell type specific expression |
| CN113444744A (zh) * | 2021-06-28 | 2021-09-28 | 北京鼎成肽源生物技术有限公司 | 一种用于基因编辑NK细胞的mRNA模板及构建方法、mRNA的体外转录方法和应用 |
| CN114107347B (zh) * | 2021-11-24 | 2022-10-28 | 中国人民解放军空军军医大学 | 一种基于具有按需抗炎功能、装载炎症响应型mRNA的工程化外泌体及其构建方法和应用 |
| IL318039A (en) * | 2022-07-10 | 2025-02-01 | Precigen Inc | Polycistronic microRNA constructs for immune checkpoint inhibition |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004529607A (ja) * | 2000-09-15 | 2004-09-30 | キュラジェン コーポレイション | ヒトポリヌクレオチドおよびそれによってコードされるポリペプチド |
| EP2140879A1 (en) * | 2001-05-09 | 2010-01-06 | M'S Science Corporation | Composition and method for treating cancer using herpes virus |
| MXPA05013879A (es) * | 2003-06-18 | 2006-06-27 | Genelux Corp | Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos. |
| WO2005013901A2 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| WO2009012263A2 (en) | 2007-07-18 | 2009-01-22 | The Trustees Of Columbia University In The City Of New York | Tissue-specific micrornas and compositions and uses thereof |
| WO2010053572A2 (en) | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| US8945531B2 (en) * | 2010-02-19 | 2015-02-03 | The University Of Tokyo | Recombinant herpes virus and pharmaceutical composition containing the same |
| PT3682905T (pt) * | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| ES2923757T3 (es) * | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| CA3285826A1 (en) | 2012-02-22 | 2026-03-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| PT2922554T (pt) * | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| US20160243221A1 (en) * | 2013-10-18 | 2016-08-25 | Moderna Therapeutics, Inc. | Compositions and methods for tolerizing cellular systems |
| DK3184641T3 (da) * | 2013-10-28 | 2020-08-03 | Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education | Onkolytisk hsv-vektor |
| KR20160079114A (ko) * | 2013-11-11 | 2016-07-05 | 아르모 바이오사이언시스 인코포레이티드 | 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법 |
| US20170202979A1 (en) * | 2014-07-17 | 2017-07-20 | Modernatx, Inc. | Terminal modifications of polynucleotides |
| WO2016040395A1 (en) * | 2014-09-08 | 2016-03-17 | Massachusetts Institute Of Technology | Rna-based logic circuits with rna binding proteins, aptamers and small molecules |
| EP3663403A1 (en) * | 2014-09-26 | 2020-06-10 | University of Massachusetts | Rna-modulating agents |
| WO2016100812A1 (en) * | 2014-12-19 | 2016-06-23 | Moderna Therapeutics, Inc. | Terminal modifications of polynucleotides |
| EP3217993A1 (en) * | 2015-07-20 | 2017-09-20 | Virttu Biologics Limited | Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood |
| EP3359670B2 (en) * | 2015-10-05 | 2024-02-14 | ModernaTX, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| US10688164B2 (en) * | 2015-11-20 | 2020-06-23 | Oregon Health & Science University | CMV vectors comprising microRNA recognition elements |
| AU2017212713B2 (en) * | 2016-01-27 | 2023-01-19 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| CA3042015A1 (en) | 2016-10-26 | 2018-05-03 | Modernatx, Inc. | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof |
| WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
| GB201714430D0 (en) | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| US20200376142A1 (en) | 2018-02-19 | 2020-12-03 | Combined Therapeutics, Inc. | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids |
| JP7539723B2 (ja) * | 2020-02-21 | 2024-08-26 | コンバインド セラピューティクス インコーポレイテッド | コード化リボ核酸の器官保護発現及び調節のための組成物並びに方法 |
-
2017
- 2017-09-07 GB GBGB1714430.4A patent/GB201714430D0/en not_active Ceased
-
2018
- 2018-09-06 CA CA3074293A patent/CA3074293A1/en active Pending
- 2018-09-06 MX MX2020002568A patent/MX2020002568A/es unknown
- 2018-09-06 RU RU2020112990A patent/RU2020112990A/ru unknown
- 2018-09-06 CN CN201880066146.2A patent/CN111212650A/zh active Pending
- 2018-09-06 EP EP18792572.2A patent/EP3678673B1/en active Active
- 2018-09-06 WO PCT/US2018/049772 patent/WO2019051100A1/en not_active Ceased
- 2018-09-06 JP JP2020536493A patent/JP2020533411A/ja active Pending
- 2018-09-06 KR KR1020207009937A patent/KR102741572B1/ko active Active
- 2018-09-06 AU AU2018328289A patent/AU2018328289B2/en active Active
- 2018-09-06 PT PT187925722T patent/PT3678673T/pt unknown
- 2018-09-06 ES ES18792572T patent/ES2942890T3/es active Active
- 2018-09-06 PL PL18792572.2T patent/PL3678673T3/pl unknown
- 2018-09-06 EP EP23153161.7A patent/EP4218770A3/en active Pending
-
2019
- 2019-02-19 MX MX2020008606A patent/MX2020008606A/es unknown
-
2020
- 2020-03-06 US US16/811,504 patent/US11359212B2/en active Active
-
2022
- 2022-03-28 US US17/706,522 patent/US12195746B2/en active Active
-
2023
- 2023-08-03 JP JP2023127023A patent/JP2023159160A/ja active Pending
-
2024
- 2024-02-02 JP JP2024015220A patent/JP2024059656A/ja active Pending
- 2024-05-16 JP JP2024080380A patent/JP2024122983A/ja active Pending
- 2024-12-17 US US18/984,898 patent/US20250129383A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4218770A2 (en) | 2023-08-02 |
| US20200255863A1 (en) | 2020-08-13 |
| WO2019051100A1 (en) | 2019-03-14 |
| MX2020008606A (es) | 2020-09-21 |
| EP4218770A3 (en) | 2023-08-09 |
| KR20200104282A (ko) | 2020-09-03 |
| RU2020112990A (ru) | 2021-10-07 |
| GB201714430D0 (en) | 2017-10-25 |
| EP3678673A1 (en) | 2020-07-15 |
| CN111212650A (zh) | 2020-05-29 |
| US11359212B2 (en) | 2022-06-14 |
| JP2023159160A (ja) | 2023-10-31 |
| US20220220506A1 (en) | 2022-07-14 |
| CA3074293A1 (en) | 2019-03-14 |
| RU2020130763A3 (enExample) | 2022-03-22 |
| ES2942890T3 (es) | 2023-06-07 |
| JP2020533411A (ja) | 2020-11-19 |
| PT3678673T (pt) | 2023-04-24 |
| US12195746B2 (en) | 2025-01-14 |
| JP2024059656A (ja) | 2024-05-01 |
| EP3678673B1 (en) | 2023-01-25 |
| KR102741572B1 (ko) | 2024-12-10 |
| RU2020112990A3 (enExample) | 2022-03-05 |
| AU2018328289B2 (en) | 2025-07-10 |
| RU2020130763A (ru) | 2022-03-21 |
| AU2018328289A1 (en) | 2020-03-19 |
| JP2024122983A (ja) | 2024-09-10 |
| PL3678673T3 (pl) | 2023-07-10 |
| US20250129383A1 (en) | 2025-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4218770A3 (en) | Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue | |
| Yang et al. | Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis | |
| SA522432139B1 (ar) | بروتينات ربط متعددة الخصوصية لمعالجة السرطان | |
| Yeom et al. | Supramolecular hydrogels for long‐term bioengineered stem cell therapy | |
| MX2026002469A (es) | Nuevas moleculas de acido nucleico artificiales | |
| MX348817B (es) | Metodos para tratar cancer y estados no neoplasicos. | |
| ZA202002094B (en) | Trispecific proteins and methods of use | |
| JOP20200313A1 (ar) | أجسام مضادة dll3-cd3 ثنائية الخاصية | |
| RU2017126610A (ru) | Терапевтические композиции и способы против злокачественных опухолей с молекулами рнки, направленными против hsp47 | |
| BR112014008932A2 (pt) | bicamadas lipídicas suportadas em nanopartículas porosas (protocélulas) para administração direcionada, incluindo a administração transdérmica de uma carga e métodos associados | |
| MY193112A (en) | Anti pd-1 and anti-lag3 antibodies for cancer treatment | |
| NZ739133A (en) | Cellular targeted active ingredient delivery system | |
| WO2011119628A3 (en) | Compositions and methods for self-adjuvanting vaccines against microbes and tumors | |
| GB2578394A (en) | Platform for generating safe cell therapeutics | |
| MX2020011290A (es) | Ligandos dirigidos a la integrina y sus usos. | |
| BRPI0411526A (pt) | vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos | |
| Su et al. | PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth | |
| ZA202207211B (en) | Peptide docking vehicle for targeted nucleic acid delivery | |
| BR112017027985A2 (pt) | peptídeos terapêuticos e métodos de uso dos mesmos | |
| MX2021001423A (es) | Vectores virales encapsulados en polimero para terapia genica. | |
| WO2019147743A8 (en) | Structure-guided chemical modification of guide rna and its applications | |
| SG10201807554QA (en) | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment | |
| MX2021014867A (es) | Metodos y composiciones para el tratamiento del cancer con adyuvantes dirigidos al cancer. | |
| WO2021081457A3 (en) | Methods and agents for enhancing t cell therapies | |
| Song et al. | The potential applications of artificially modified exosomes derived from mesenchymal stem cells in tumor therapy |